首页> 美国卫生研究院文献>Springer Open Choice >Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

【2h】

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

机译：ponatinib对难治性血液系统恶性肿瘤患者QTc间隔的潜在影响分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeCardiac dysfunction, particularly QT interval prolongation, has been observed with tyrosine kinase inhibitors approved to treat chronic myeloid leukemia. This study examines the effects of ponatinib on cardiac repolarization in patients with refractory hematological malignancies enrolled in a phase 1 trial.

机译：目的已观察到批准用于治疗慢性粒细胞白血病的酪氨酸激酶抑制剂的心脏功能异常，特别是QT间隔延长。这项研究检查了ponatinib对1期试验招募的难治性血液系统恶性肿瘤患者心脏复极的影响。

著录项

期刊名称 Springer Open Choice
作者
Daryl Sonnichsen; David J. Dorer; Jorge Cortes; Moshe Talpaz; Michael W. Deininger; Neil P. Shah; Hagop M. Kantarjian; Dale Bixby; Michael J. Mauro; Ian W. Flinn; Jeffrey Litwin; Christopher D. Turner; Frank G. Haluska;
展开▼
作者单位

展开▼
年(卷),期 -1(71),6
年度 -1
页码 1599–1607
总页数 9
原文格式 PDF
正文语种
中图分类外科学;
关键词
Ponatinib BCR-ABL Chronic myeloid leukemia Philadelphia chromosome Drug safety Electrocardiography;

机译：Ponatinib;BCR-ABL;慢性粒细胞白血病;费城染色体;药物安全性;心电图;

相似文献

外文文献
中文文献
专利

1. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies [J] . SonnichsenD., DorerD.J., CortesJ., Cancer chemotherapy and pharmacology. . 2013,第6期

机译：ponatinib对难治性血液系统恶性肿瘤患者QTc间隔的潜在影响分析
2. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies [J] . HanT.H., ChenR., AdvaniR., Cancer chemotherapy and pharmacology. . 2013,第1期

机译：Brentuximab vedotin不会导致CD30阳性血液系统恶性肿瘤患者的临床相关QTc间隔延长
3. Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph plus Malignancies Treated with Ponatinib [J] . Pritchard Justin R., Schmitt Michael W., Hodgson J. Graeme, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：帕纳替尼治疗难治性Ph +恶性肿瘤患者的复合突变亚克隆起源分析
4. Designing a conversational agent for patients with hematologic malignancies: Usability and Usefulness Study [C] . Maria Chatzimina, Helen Papadaki, Charalampos Pontikoglou, IEEE EMBS International Conference on Biomedical and Health Informatics . 2021

机译：设计血液学恶性肿瘤患者的会话剂：可用性和有用性研究
5. Efficacy of a Mindfulness-Based Intervention in Reducing Burnout and Increasing Resilience in Registered Nurses Caring for Patients with Hematologic Malignancies [D] . Kopp, Erin Allyson. 2020

机译：基于令人思想的干预在减少倦怠和增加注册护士的恢复力的功效，为血液学恶性肿瘤的患者提供了增加
6. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies [O] . T. H. Han, R. Chen, R. Advani, -1

机译：Brentuximab vedotin不会导致CD30阳性血液系统恶性肿瘤患者的临床相关QTc间隔延长
7. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies [O] . Daryl Sonnichsen, David J. Dorer, Jorge Cortes, 2013

机译：ponatinib对难治性血液系统恶性肿瘤患者QTc间隔的潜在影响分析

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

摘要

著录项

相似文献

相关主题

期刊订阅